FluoSphera is the only company with a suite of systemic and high-throughput in vitro drug discovery solutions that reduce costs and increase speed and effectiveness.
FluoSphera’s chip-free 3D cell culturing solutions mimic the natural physiology of the human body, its complex biology, and disease states, enabling researchers to study the human response to systemic drug delivery rapidly and precisely.
FluoSphera empowers its customers and partners to de-risk drug discovery
Multiplexing, high-throughput, modular technology allows for individual project customization for rapid evaluation of >1000 compounds with 28 simultaneous readouts.
Systemic Exposure recapitulates human first-pass liver Drug Metabolism and PharmacoKinetics (DMPK) allowing for early detection of drug systemic effects normally only detected in animal models or patients.
Optimizes pre-clinical testing and animal model species selection, reducing unnecessary costs while enhancing the likelihood of clinical trial success.
Subscribe to our Investor Newsletter to keep up with FluoSphera’s milestones ahead of the next fundraising round